Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Recruiting · NCT06408688 · Registry updated 2024-12-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors | Advanced Solid Tumor | Recruiting | Phase 4 | 2024-12-27 | NCT06408688 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Hospital, Basel, Switzerland | 243 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Kantonsspital Baselland | Liestal | Switzerland | 12 |
| Kantosspital Baden AG | Baden | Switzerland | 1 |
| Tumor- und Brustzentrum Ostschweiz | Sankt Gallen | Switzerland | 3 |
| Universitätsspital Basel | Basel | Switzerland | 43 |